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Abstract
Background: Relaxin is the endogenous ligand of the G-protein coupled receptor RXFP1,
previously known as LGR7. In humans relaxin can also activate, but with lower affinity, the closely
related receptor for the insulin-like peptide from Leydig cells, RXFP2, previously known as LGR8.
The lack of relaxin impairs male fertility but the precise distribution and the function of relaxin
receptors in the male reproductive tract is not known. We investigated the distribution of Rxfp1
and Rxfp2 in the reproductive tract of the male rat and the function of relaxin in the vas deferens,
a tissue with high expression of both receptors.
Methods: The presence of mRNA for Rxfp1 and Rxfp2 was investigated in testes, cultured Sertoli
cells, epididymis, vas deferens, seminal vesicle, prostate, and spermatozoa by RT-PCR and Southern
blot. Protein expression in the testis, vas deferens, primary culture of Sertoli cells, and spermatozoa
was assessed by immunohistochemistry and immunofluorescence. The role of relaxin in the vas
deferens was evaluated by contractility studies and radioimmunoassay of cAMP production. The
effect of relaxin on mRNA levels for metalloproteinase-7 was measured by Northern blot.
Results: Transcripts for Rxfp1 and Rxfp2 were present in almost all parts of the male reproductive
tract, with high levels in testis and vas deferens. Both receptors were immunolocalized in late stage
germ cells but not in mature spermatozoa, although mRNAs for both receptors were also present
in mature spermatozoa. Rxfp1 but not Rxfp2 was detected in cultured Sertoli cells. Strong
immunostaining for Rxfp1 and Rxfp2 was seen in muscular and epithelial layers of the vas deferens
and in arteriolar walls. Relaxin did not affect contractility and cyclic AMP production of the vas
deferens, but increased the levels of mRNA for metalloproteinase-7.
Conclusion: Rxfp1 and Rxfp2 are widely and similarly distributed throughout the male
reproductive tract. Our results suggest that Rxfp1 on spermatids and Sertoli cells may be important
in spermatogenesis. Relaxin in the vas deferens does not affect contractility, but may affect vascular
compliance and collagen and matrix remodeling.
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Relaxin belongs to a superfamily of hormones structurally
related to insulin that includes, among others, the relaxins
1, 2 and 3 and the insulin-like peptide from Leydig cells
(INSL3) [1]. Humans have three forms of relaxin (H1, H2
and H3), encoded by three different genes, but other
mammals like rat, mouse and pig seem to have only two
forms of relaxin (relaxins 1 and 3) [1]. The recent discov-
ery that relaxin can bind to and activate the G-protein-
coupled receptors (GPCRs) LGR7 and LGR8 [2] was a
major breakthrough in the field. Recently the IUPHAR
commitee renamed these receptors to RXFP1 and RXFP2
respectively [3]. The human relaxins H1 and H2 and por-
cine relaxin 1 strongly bind to and activate both RXFP1
and RXFP2 with almost the same affinity, but the rat
relaxin 1 binds only weakly to Rxfp2 [2,4]. Relaxin H3 is
a selective ligand for RXFP1 but is also able to bind to
GPCR135 (RXFP3) and GPCR142 (RXFP4) [5,6]. Insl3 is
a selective ligand for Rxfp2 [7].
Relaxin is well known for its relaxing effect on the pubic
ligament before parturition, but many other actions have
been discovered for this hormone [1,8]. The physiological
role of relaxin in the male is not so well defined. In
humans and many other mammals, relaxin is produced
by the prostate and released almost exclusively in the sem-
inal fluid. The mRNA for RXFP1 and RXFP2 has been
detected in testis and in prostate, and the mRNA for
RXFP2 has also been detected in gubernaculum [3]. A
detailed study of the expression of Rxfp2 in the testis iden-
tified the mRNA in Leydig and germ cells of the rat and the
protein in human Leydig and germ cells [9]. RXFP2 was
also present in the human epididymis [9].
With the recent availability of knockout animals for
relaxin or its receptors it has been possible to establish the
physiological importance of this hormone. Relaxin has an
antifibrotic effect in several tissues, and the relaxin knock-
out mouse is a model of fibrosis [10-12]. Relaxin inter-
feres with collagen metabolism and increases the
expression and activity of metalloproteinases (MMPs) in
uterine, cardiac, vascular and renal tissues [13-16]. In the
reproductive tract of female mice, the disruption of the
relaxin or the Rxfp1 gene causes the same abnormalities:
an absence of the relaxation and elongation of the inter-
pubic ligament and impaired nipple development
[17,18]. In male mice the disruption of the relaxin gene
causes a delayed development of the reproductive tract,
with an arrest of the sperm maturation [10], but disrup-
tion of Rxfp1 does not always cause the same abnormali-
ties. Kamat et al. [19] did not find abnormalities in the
testes and prostate of Rxfp1 knockout mice. Krajnc-
Franken et al. [18], using a different strain of knockout
mice, observed impaired spermatogenesis, leading to
azoospermia and reduced fertility in animals from the
first generations but the following generations or older
animals had normal fertility.
The interaction of Insl3 with Rxfp2 controls the differen-
tiation of gubernaculum, the caudal genitoinguinal liga-
ment critical for testicular descent, and deletion of Insl3 or
Rxfp2 causes cryptorchidism [20]. Transgenic overexpres-
sion of relaxin did not prevent cryptorchidism in Insl3-
knockout animals [21]. Therefore it seems that relaxin
does not physiologically activate RXFP2, although both
RXFP1 and RXFP2 can bind relaxin in vitro. Nevertheless,
it is possible that binding of relaxin to RXFP2 contributes
to some of the actions of relaxin in some species.
The aim of the present study was to map the expression of
Rxfp1 and Rxfp2 in the reproductive tract of the male rat.
The presence of messenger RNA was investigated in testis,
primary culture of Sertoli cells, epididymis (caput and
cauda), vas deferens, seminal vesicle, prostate, and sper-
matozoa by RT-PCR and Southern blot. The localization
of both receptors was investigated by immunostaining in
the vas deferens, testis, primary culture of Sertoli cells, and
spermatozoa. The functional role of relaxin was investi-
gated in the vas deferens by assessing the ability of the
hormone to affect contractility, cyclic AMP production,
and the transcription of metalloproteinase-7 (Mmp-7), a
member of the stromelysin subfamily of MMPs preferen-
tially expressed in epithelial cells of the reproductive tract
and present in human semen [22,23].
Methods
Animals and biological samples
Male Wistar rats were housed in the Animal Facility at the
Instituto Nacional de Farmacologia, UNIFESP-EPM, and
maintained on a 12 h light, 12 h dark lighting schedule, at
23°C, with food and water available ad libitum. All proce-
dures were approved by the Research Ethical Committee
from UNIFESP-EPM.
Tissues were removed from 120-day old rats. Sertoli cells
were isolated from testes removed from 15-day old rats
and cultured as previously described [24].
To obtain spermatozoa from the epididymis, a small inci-
sion was made in the cauda epididymis and a syringe
filled with PBS (10 mM sodium phosphate, 0.15 M NaCl,
pH 7.4) inserted into the vas deferens. The epididymal
content was collected in a tube by retrograde washes. The
samples were washed with PBS and centrifuged at 1000 ×
g for 10 min at room temperature. Somatic contaminants
were removed by two sequential centrifugations at 400 ×
g for 20 min at room temperature through a gradient of
40:80 Percoll (Amersham Biosciences, Piscataway, NJ) in
PBS. The pellet containing the viable spermatozoa wasPage 2 of 12
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and immunofluorescence.
Reverse transcriptase reaction followed by polymerase 
chain reaction (RT-PCR)
Total RNA was obtained with the TRIzol reagent (Invitro-
gen, Carlsbad, CA) according to the standard protocol
[25] and checked for ribosomal RNA integrity by agarose
gel electrophoresis. A 2:1 ratio of sharp and clear ethidium
bromide stained 28S:18S ribosomal RNA bands was
observed for all samples. The first strand cDNA was syn-
thesized at 42°C with the Thermoscript RT-PCR System
(Invitrogen) and the random hexamers supplied with this
kit.
The primers designed for amplification of Rxfp1 and
Rxfp2 transcripts were complementary to regions in differ-
ent exons to exclude amplification due to genomic DNA
contamination. Table 1 presents a list of all primers used
in the present study. The housekeeping gene glyceralde-
hyde-3-phosphate dehydrogenase (Gapdh) was amplified
as a control of the amount of cDNA used in the PCRs. The
size of the expected products was compared to a DNA lad-
der (1 Kb plus or 100 bp ladder, Invitrogen). PCR prod-
ucts were subjected to automated DNA sequencing with
the DYEnamic ET Terminator Sequencing Kit (Amersham
Biosciences).
The conditions for the PCRs were as follows: 2 µL cDNA,
0.5 to 1.0 µM of each primer, 0.2 to 0.6 mM dNTP mix-
ture, 2 or 4 mM MgCl2, 2.5 U Taq polymerase (Invitro-
gen), in a 25 µL final volume. To validate a
semiquantitative analysis of the results, we determined
the linear range for the PCRs, measuring the amount of
product in function of the number of thermal cycles. To
amplify the transcript from a transmembrane region of
Rxfp1 (exon 14 to exon 16) the following thermal cycles
were used: 1 denaturing cycle at 94°C for 5 min; 25 to 45
cycles at 94°C for 1 min, 46°C for 1 min and 72°C for 2
min, with a final extension at 72°C for 7 min. To amplify
the transcript from aminoterminal to transmembrane
region (exons 4 to 16) of Rxfp1 the following thermal
cycles were used: 1 denaturing cycle at 94°C for 5 min;
35–55 cycles at 94°C for 1 min, 55°C for 1 min and 72°C
for 2 min, with a final extension at 72°C for 7 min. For
amplification of Rxfp2 the following cycle program was
used: 1 denaturing cycle at 94°C for 5 min; a touch down
of 4 cycles at 94°C for 1 min, 55°C for 1 min and 72°C
for 2 min, 4 cycles at 94°C for 1 min, 50°C for 1 min and
72°C for 2 min, followed by 15 to 35 cycles at 94°C for 1
min, 45°C for 1 min and 72°C for 2 min, with a final
extension at 72°C for 7 min. For amplification of the
Mmp-7 and Gapdh transcripts we used an initial denatur-
ation at 94°C for 5 min, 20 to 40 cycles at 94°C for 1 min,
62°C for 1 min and 72°C for 2 min, with a final extension
at 72°C for 7 min. We chose 35 cycles for Rxfp1 (trans-
membrane region transcript), 50 cycles for Rxfp1 (ami-
noterminal and transmembrane regions), 25 cycles for
RXFP2 and 30 cycles for Gapdh and Mmp-7 to assure the
linear range of the exponential curve of PCR amplifica-
tion. The PCR products were resolved on agarose gels
(1.5%) containing ethidium bromide (0.5 µg/ml) and vis-
ualized under UV transilumination. The bands corre-
sponding to the expected size were submitted to
densitometric analysis with Scion Image software (Scion
Corp., 2000) and normalized based on the intensity of the
Gapdh related product.
Southern blot analysis
In tissues with low expression of Rxfp1 and Rxfp2, the RT-
PCR products were submitted to a Southern blot analysis.
The PCR products were subjected to electrophoresis in a
1.5% agarose gel. The gel was denatured and neutralized
and the nucleic acid bands were transferred by capilarity
to a nylon membrane (Zeta Probe GT, Bio-Rad, Hercules,
CA). Membranes were cross-linked with UV light and pre-
hybridized for 3 h at 65°C in 6 × SSC (standard saline cit-
rate) containing 5 × Denhardt's solution, 0.5% SDS, and
100 µg/mL sheared denatured salmon sperm DNA.
Hybridization was performed overnight at 65°C in the
same solution containing probes that were labeled with
32P (T7 Quick Prime kit, Amersham Biosciences). The
Table 1: Oligonucleotides used for RT-PCR.
Transcript Orientation Sequence Nucleotide position
Rxfp1 [GenBank:NM_201417] forward 5'-TGGAGCCCAGATTTATTCAGTGG-3' 1722 to 1744 (exon 14)
forward 5'-TGTGACGAAGCCAATTTACG-3' 337 to 356 (exon 4)
reverse 5'-GCCACATTTCCACCCAGATGAATG-3' 2173 to 2150 (exon 16)
Rxfp2 [GenBank:NM_001012475] forward 5'-TTCAGCGACCTTCACCTTCT-3' 922 to 941 (exon 11)
reverse 5'-CTTCTGCTTGGTCGTAATGAAGTG-3' 1696 to 1673 (exon 14)
Mmp-7 [GenBank:NM_012864] forward 5'-CGGAGATGCTCACTTTGACA-3' 603 to 622
reverse 5'-TGCAAAACCCATCCACAGTA-3' 924 to 905
Gapdh [GenBank:NM_017008.3]
forward 5'-TGGGAAGCTGGTCATCAACGG-3' 262 to 282
reverse 5'-TGGCAGTGATGGCATGGACTG-3' 620 to 600Page 3 of 12
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nucleotides 1722 – 2173 of the rat Rxfp1 cDNA. The
Rxfp2 probe was a 305 bp product corresponding to posi-
tions 1392 to 1696 of the rat Rxfp2 cDNA. The mem-
branes were washed 3 times for 15 min with 2 × SSC/0.1%
SDS at room temperature, and 2 times for 15 min with 1
× SSC/0.1% SDS at 65°C. Membranes were exposed for
autoradiography and results were analyzed by densitome-
try with Scion Image software. The size of the 32P-labeled
PCR products was always compared with the standard
DNA ladder and with the product from myometrium. We
did not detect any non-specific hybridization with the 32P-
labeled probes under the high stringency conditions used
in the Southern blot.
Recording of isometric contractions of the uterus and the 
vas deferens
Porcine relaxin was obtained from National Hormone
Peptide Program (Torrance, CA). The vas deferens was
removed from 120-day old male rats. As a control we used
the uterus of rats that received a subcutaneous injection of
50 µg estradiol hexahydrobenzoate (Benzoginoestryl,
Abbott, Brazil) 16 h before the experiments. Tissues were
suspended under 0.5 g tension in 10 mL chambers con-
taining aerated nutrient solution [26] (composition mM:
NaCl, 137; KCl, 5.6, CaCl2 1.8, NaH2PO4 0.4, NaHCO3 15
mM and glucose 8) at 30°C. Isometric contractions were
measured by force-displacement transducers connected to
a physiograph (Gemini 7070, Ugo Basile, Comerio VA,
Italy).
To test if relaxin induces relaxation of smooth muscles we
used three protocols. In the first protocol we took advan-
tage of the fact that the vas deferens of castrated animals
develops spontaneous contractions [27]. The spontane-
ous isometric contractions of vas deferens isolated from
30 days castrated rats were recorded for 30 minutes before
and after addition of relaxin (0.01, 0.05, 0.1 or 0.5 µg/ml)
or forskolin (50 µM; Sigma Chemical Company).
In the second protocol, we tested the contractile response
of the organ to 2.5 µM noradrenaline before and after 30
minutes of incubation with relaxin (0.01, 0.05, 0.1 or 0.5
µg/ml) or forskolin (50 µM).
For the third protocol, the vas deferens was pre-contracted
by depolarizing the cells with a solution in which Na was
replaced with an equimolar amount of K. The resulting
response consisted of a phasic contraction that lasted
about 1 min, followed by a less intense tonic contraction
that lasted about 10 min. Relaxin (cumulative concentra-
tion-response curve with 0.01, 0.05, 0.1 and 0.5 µg/ml),
forskolin (50 µM), or IBMX (500 µM) were added 5 min
after addition of the depolarizing medium, when the
tonic contraction was stable. In control experiments the
uterus was pre-contracted with a depolarizing solution
where 15% of the NaCl was substituted by an equimolar
amount of KCl [28]. After stabilization of the contraction,
relaxin (0.25 µg/ml) was added.
Cyclic AMP assay
The vas deferens was removed from 120-day old rats,
freed from connective tissue, opened, and cut in squares
of approximately 5 mm2. The fragments were incubated
for 30 min at 30°C in 6 well plates with gentle shaking
and aeration in 1 ml nutritive solution [26] containing 0.5
mM of the phosphodiesterase inhibitor isobuthyl-methyl-
xanthine (IBMX, Sigma Chemical Company, St. Louis,
MO). Tissues were stimulated for 10 minutes with 0.1,
0.5, 1, 2, or 5 µg/mL of porcine relaxin or with 50 µM for-
skolin (Calbiochemical, San Diego, CA). Controls were
incubated with PBS. The reaction was stopped on ice. The
tissue fragments were immediately frozen in liquid nitro-
gen and homogenized in cold 6% trichloroacetic acid to
give a 10% (w/v) homogenate. The homogenate was cen-
trifuged at 2,000 × g for 15 min at 4°C. The supernatant
was washed 5 times with 5 volumes of water saturated die-
thyl ether and the remaining aqueous phase was dried in
a speed vac. Cyclic AMP content was measured by radio-
immunoassay (cyclic AMP 125I Biotrak assay system,
Amersham Biosciences). The values were read from a
standard curve obtained with 25–1600 fmol cyclic AMP.
Results were expressed as a percentage of the value of non-
stimulated controls and represent the mean and SEM of
three independent experiments.
Detection of mRNA for metalloproteinase-7 (Mmp-7) in 
the vas deferens after relaxin treatment
The vas deferens was removed, freed of connective tissues,
and cut in four. The pieces were left equilibrating for 30
min at 30°C in 1 ml nutritive solution [26] in 6 well
plates with gentle shaking and aeration. The control tissue
(no relaxin) was incubated for an additional 120 min in
the medium. The other tissues were similarly incubated
for 120 min, with relaxin (1 µg/ml) present during the last
30, 60, or 120 min of the incubation period. The reaction
was stopped on ice and the tissue fragments were imme-
diately frozen in liquid nitrogen. Total RNA was extracted
with TRIzol as described earlier.
Mmp-7 mRNA levels were measured by Northern blot as
follows. Five µg total RNA were separated on an agarose/
MOPS gel. The separated RNAs were transferred by capi-
larity to a nylon membrane and crosslinked with UV light.
The membranes were prehybridized and hybridized as
described for the Southern blot protocol with a 32P-
labeled 322 bp PCR product corresponding to nucleotides
603 to 924 of the rat Mmp-7 cDNA. The membranes were
then washed and exposed for autoradiography and the
results were analyzed as described for the Southern blot.Page 4 of 12
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labeled probe specific for Gapdh, obtained by PCR as
described before. After autoradiography and densitome-
try, results were normalized based on Gapdh expression.
Immunohistochemistry
The uterus (control), vas deferens and testis from 120 day
old rats were removed and frozen in liquid nitrogen. Sec-
tions of the frozen tissues (8 µm) were obtained in cryo-
stat at -20°C and transferred to silanized slides. The
sections were kept for 30 minutes at room temperature,
fixed for 20 minutes in 4% paraformaldehyde buffered
with PBS, incubated for 5 minutes in 0.1 M glycine, and
treated with 0.3% hydrogen peroxide for 10 minutes to
remove endogenous peroxidase activity. The sections were
incubated in blocking buffer (PBS with 0.01% saponin
and 3% albumin) for one hour at room temperature in a
humidified chamber. Endogenous biotin was blocked
with the Avidin/Biotin Blocking Kit (Vector Laboratories,
Burlingame, CA).
The sections were incubated overnight at 4°C with the pri-
mary antibodies diluted in blocking buffer (1:100, 1:200
or 1:300). As a primary antibody against Rxfp1 we used
rabbit anti-human LGR7 (735–757) (H001-53, Phoenix
Pharmaceuticals, Belmont, CA). The primary antibody
against Rxfp2 was rabbit anti-human LGR8 (737–754)
(H001-54, Phoenix Pharmaceuticals). Both antibodies
recognize rat proteins and have been well characterized
for human [29,30] and rat tissues [31,32]. The sections
were rinsed 3 times, 5 min each, with the blocking buffer,
and incubated for 1 h with the secondary antibody (1:300
dilution of biotinylated goat anti-rabbit IgG (Santa Cruz
Biotechnologies, Santa Cruz, CA). The sections were
rinsed again 3 times with blocking buffer and incubated
for 1.5 h at room temperature with avidin-conjugated
horseradish peroxidase complex (ABC system, Santa Cruz
Biotechnologies). Peroxidase activity was revealed by
incubation with 3,3'-diaminobenzidine (DAB, 0.5 mg/
ml) in 0.01% H2O2 for 3 min. The sections were washed,
dried at room temperature, and counterstained with
methylene blue.
Slides were examined with a Nikon E800 microscope
(Melville, NY) and images were captured with a digital
camera and analyzed with Media Cybernetics software
(Silver Spring, MD). Negative controls (tissues incubated
with non-immune rabbit serum instead of the primary
antibody) were run in parallel with the tissues of interest.
Immunofluorescence
Sertoli cells were plated on gelatin-coated coverslips in 6-
well plates (2 × 105 cells/well). After five days in culture
they were fixed with 3.7% formaldehyde for 30 min at
37°C. They were washed 3 times with PBS and blocked
with PBS containing 3% bovine serum albumin (BSA) for
30 min at room temperature. They were washed again
with PBS. The cells were incubated for 2 h at room temper-
ature with primary antibody (1:100 or 1:300 dilution of
rabbit anti-human RXFP1 or RXFP2). To permeabilize
samples, 0.1% saponin was used in the blocking buffer
and during incubation with the antibodies. Cells were
washed and incubated with 1:300 dilution of a fluores-
cent secondary antibody (30 min, goat anti-rabbit IgG,
Alexafluor 594, Molecular Probes, Eugene, OR).
Viable spermatozoa were separated with a Percoll gradient
as described before, spread on silanized slides, and dried
for 30 min. They were fixed with 2% formaldehyde, incu-
bated for 5 min with PBS containing 0.1 M glycine, rinsed
with PBS, and incubated with blocking buffer (PBS with
1% BSA and 0.1% saponin) for 10 min. Cells were washed
with PBS and incubated for 1 h with a 1:50, 1:100, or
1:300 dilution of the primary antibody. They were washed
again and incubated for 30 min with the secondary anti-
body. Nuclei were visualized by staining with DAPI (4', 6-
diamine-2-phenylindol). Negative controls were run in
the absence of the primary antibody. The slides were
examined with a Nikon E800 fluorescence microscope.
Statistical analysis
Data were expressed as mean ± SEM. Statistical analysis
was carried out by analysis of variance (ANOVA) followed
by Newman-Keuls test for multiple comparisons or by
Student's t-test to compare the differences between two
data (Sigmastat version 2.03, SPSS Inc). P values < 0.05
were accepted as significant.
Results
Rxfp1 and Rxfp2 messenger RNA in the reproductive tract 
of the male rat
In the testis and the vas deferens transcripts for Rxfp1 (452
bp product) and Rxfp2 (775 bp product) could always be
easily visualized on ethidium bromide-stained agarose
gels (Figure 1A and 1C). A Southern blot analysis after RT-
PCR with several rat tissues allowed mapping the presence
of the mRNA for Rxfp1 and Rxfp2 even in tissues of the
male reproductive tract with low expression of the tran-
scripts (Figure 1B). Our aim was not to quantify the tran-
scripts for both proteins, but these semi-quantitative
methods clearly show that mRNA levels for Rxfp1 were
high in testis, vas deferens, myometrium, endometrium,
heart, and brain, while lower levels of Rxfp1 were found
in the other parts of the reproductive tract. The distribu-
tion of Rxfp2 mostly paralleled that of Rxfp1. Notable dif-
ferences were remarkably high Rxfp2 levels in the caput
epididymis, and the absence of Rxfp2 in the prostate.
Since a splice variant for RXFP1 was detected in rat tissues
with a deletion in exon 4 that leads to a truncated form thePage 5 of 12
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detected in testis and vas deferens contained that region,
using a forward primer complementary to a region in
exon 4. Figure 1C shows that a transcript containing exon
4 to exon 16 (1837 bp product) was present in the myo-
metrium, testis and vas deferens.
We detected a weak signal for both Rxfp1 and Rxfp2 tran-
scripts in spermatozoa removed from the cauda epidi-
dymis (Fig. 2), but we had to use larger amounts of cDNA
to visualize the signal for the Rxfp1 transcript. The high
levels of Rxfp1 and Rxfp2 mRNA in the vas deferens were
not due to spermatozoa, since the mRNA levels in the vas
deferens were about the same after washout of the lumi-
nal content.
Immunolocalization of Rxfp1 and Rxfp2 proteins in vas 
deferens and testis
We performed immunohistochemistry to examine what
cell types account for the high levels of mRNA for Rxfp1
(Fig. 3) and Rxfp2 (Fig. 4) in the vas deferens and the tes-
tis. Intense Rxfp1 immunostaining was detected in late
stage germ cells from the testis, but not in early stage germ
cells (Figure 3A and 3B). Diffuse staining was detected in
the basal compartment of the tubuli and in myoid cells
(Figure 3A). No significant immunostaining was seen in
negative controls incubated with non-immune serum
instead of primary antibody (inserts). Strong immunos-
taining for Rxfp1 was detected in the apical portion of epi-
thelial cells and in the longitudinal and circular muscular
layers of the vas deferens (Fig. 3C). We also detected Rxfp1
in the wall of blood vessels. Fig 3D shows an example of
Rxfp1 staining in what appears to be an arteriole, based on
Autoradiograms of the Southern blot analysis of the pres-ence of Rxfp1 and Rxfp2 mRNA in the v s deferens (NW = not w shed, W = washed to remove spermat zoa) and in sperm tozoa removed fr m the cauda epididymisFigu e 2
Autoradiograms of the Southern blot analysis of the pres-
ence of Rxfp1 and Rxfp2 mRNA in the vas deferens (NW = 
not washed, W = washed to remove spermatozoa) and in 
spermatozoa removed from the cauda epididymis. The 
amount of cDNA used from the vas deferens was 2 µL. 
Exposure to film was 2 h for Rxfp1 and 1 h for Rxfp2 tran-
scripts. Results are representative of 3 independent determi-
nations, each one with a different animal.
Rxfp1 and Rxfp2 transcripts are present throughout the reproductive tract of the male ratFigure 1
Rxfp1 and Rxfp2 transcripts are present throughout the 
reproductive tract of the male rat. [A] Agarose gel electro-
phoresis with Rxfp1 (left panel, 452 bp product) and Rxfp2 
(right panel, 775 bp product) transcripts amplified by RT-
PCR from the testis (lane 1) and vas deferens (lane 2). 
Arrows indicate the expected product. [B] Densitometric 
analysis of Southern blots of Rxfp1 (left) and Rxfp2 (right) 
transcripts amplified by RT-PCR from various tissues of the 
male reproductive tract. Results are mean ± SEM of meas-
urements with RNAs from 3 – 5 independent experiments, 
each with a different animal. [C] RT-PCR analysis of the pres-
ence of exon 4 in Rxfp1 transcripts (1837 bp product) in 
myometrium (lane M), testis (lane 1) and vas deferens (lane 
2). Result is representative of 3 independent experiments, 
each with a different animal.Page 6 of 12
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ing localized in putative smooth muscle.
Rxfp2 expression similarly was high in late stage germ
cells and absent in early stage cells, but diffuse Rxfp2
immunostaining was also present in the interstitial com-
partment (Figure 4A). It is interesting to note that the
immunostaining for both Rxfp1 (Fig. 3A) and Rxfp2 (Fig.
4A) in adjacent tubuli varied, suggesting that the expres-
sion of these proteins may be specific for certain stages of
spermatogenesis. The pattern of expression of Rxfp2 in the
vas deferens was similar to that of Rxfp1: staining was
detected in the apical portion of epithelial cells and in the
muscular layers of the organ (Figure 4B).
Spermatozoa collected from the cauda epididymis did not
show any immunofluorescence indicative of Rxfp1 and
Rxfp2 receptors (data not shown). Primary cultures of Ser-
toli cells presented immunofluorescence for Rxfp1 (Figure
5C), but not for Rxfp2 (Figure 5F). No immunofluores-
cence for Rxfp1 was detected in Sertoli cells incubated
without primary antibody (Figure 5A) or with non-
immune serum instead of primary antibody (data not
shown), and in unpermeabilized Sertoli cells where the
primary antibody did not have access to the epitope in the
carboxyterminal region of the receptor (Figure 5B).
Localization of Rxfp2 protein in the testis (A) and vas defer-ens (B)Figure 4
Localization of Rxfp2 protein in the testis (A) and vas defer-
ens (B). Immunohistochemistry for Rxfp1 (1:100 dilution of 
primary antibody) was done in cryosections of the testis and 
vas deferens; sections were counterstained with methylene 
blue. Inserts show controls incubated with non-immune rab-
bit serum instead of primary antibody. Scale bars are 5 µm. 
Results are representative of at least 3 independent determi-
nations, each with a different animal. ep = epithelial layer, in 
= interstitium, lu = lumen, m = muscular layer, sp = sperma-
tid. Arrows indicate labeled epithelial cells, arrow heads indi-
cate labeled muscular cells, and double-headed arrows 
indicate labeled spermatids.
Localization of Rxfp1 protein in the testis (A, B) and vas defe-rens (C, D)Figure 3
Localization of Rxfp1 protein in the testis (A, B) and vas defe-
rens (C, D). Immunohistochemistry for Rxfp1 (1:100 dilution 
of primary antibody) was done in cryosections of the testis 
and vas deferens; sections were counterstained with methyl-
ene blue. Inserts show controls incubated with non-immune 
rabbit serum instead of primary antibody. Scale bars are 5 
µm. Results are representative of at least 3 independent 
determinations, each one with a different animal. bv = blood 
vessel, ep = epithelial layer, lu = lumen, m = muscular layer, 
mc = myoid cells, sp = spermatid. Arrows indicate labeled 
epithelial cells, arrow heads indicate labeled muscular cells, 
double-headed arrows indicate labeled spermatids and open-
headed arrow indicates labeled myoid cells.Page 7 of 12
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To test if the relaxin receptors in muscular layer of the vas
deferens were involved in contraction we measured the
effect of relaxin on the contractility of the isolated vas def-
erens. Relaxin (0.01, 0.05, 0.1, and 0.5 µg/mL) failed to
affect the spontaneous contractions that are seen in the
isolated vas deferens of castrated rats (Fig. 6A; 0.5 µg/mL).
Forskolin completely inhibited these contractions. Pre-
treatment of the vas deferens with 0.01, 0.05, 0.1 or 0.5
µg/mL relaxin for 30 min did not affect the contractile
response to noradrenaline (Fig. 6B; 0.5 µg/mL). This con-
tractile response was strongly reduced by pre-treatment
with forskolin. When the vas deferens was precontracted
with a depolarizing solution in which Na+ was replaced
with K+, the contraction was blunted by forskolin (50 µM)
and by IBMX (500 µM), but little change was seen after a
cumulative dose-response curve with relaxin (a reduction
of 8% with a final concentration of 0.5 µg/mL, Fig. 6C).
On the other hand, 0.25 µg/mL relaxin completely relaxed
the pre-contracted uterus (Figure 6D).
Relaxin fails to affect the production of cyclic AMP, but 
increases mRNA levels for MMP-7 in the vas deferens
Since muscular activity in the vas deferens was reduced by
drugs that increase cyclic AMP levels, we investigated the
ability of relaxin to affect cyclic AMP production in the vas
deferens. We found that low to moderate concentrations
of relaxin (0.1 to 0.5 µg/ml) did not increase cyclic AMP
production (data not shown). High concentrations of
relaxin (5 µg/ml) seemed to induce a slight increase in the
cyclic AMP production, but this effect was not statistically
significant and much smaller than the effect of forskolin
(Fig. 7A).
Relaxin is a well known regulator of metalloproteinases
expression and activity both in non-reproductive and
reproductive tissues. Metalloproteinase 7 (MMP7) is an
enzyme that is present in human semen and is expressed
particularly in reproductive tissues [34,22,23]. It degrades
a wide range of extracellular matrix proteins, including
collagen [35], and activates other MMPs, including MMP2
and MMP9, which play a major role in degradation of col-
Relaxin fails to affect contractility of the vas deferensFigure 6
Relaxin fails to affect contractility of the vas deferens. [A] 
Effects of relaxin (RLX, 0.5 µg/ml) and forskolin (FKL, 50 µM) 
on spontaneous contractions of the vas deferens from cas-
trated rats. [B] Effect of pre-treatment for 30 min with RLX 
(0.5 µg/ml) or FKL (50 µM) on contractions of the vas defer-
ens induced by 2.5 µM noradrenaline; * P < 0.05 compared to 
relaxin (Student's t test). [C] Effect of RLX (0.5 µg/ml), FKL 
(50 µM) and IBMX (500 µM) on contractions of the vas defe-
rens induced by incubation in a depolarizing solution; *P < 
0.05 compared to relaxin (Newman Keuls). [D] Control 
experiment showing the relaxing effect of relaxin (RLX 0.25 
µg/ml) in rat uterus. All experimental protocols were 
repeated at least 3 times with different animals.
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*Rxfp1 and Rxfp2 receptors in cultured Sertoli cellsFigure 5
Rxfp1 and Rxfp2 receptors in cultured Sertoli cells. Recep-
tors were labeled red with immunofluorescent antibody 
against intracellular domains of the receptors, nuclei were 
labeled blue with DAPI. A and D: assay with permeabilized 
cells in the absence of the primary antibody. B and E: assay 
with non-permeabilized cells in the presence of the primary 
antibody. C and F: assay with permeabilized cells in the pres-
ence of the primary antibody. Rxfp1 antibody dilution 1:300, 
Rxfp2 antibody 1:100. Results are representative of 3 differ-
ent cell cultures.Page 8 of 12
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ml relaxin, a concentration that did not affect cyclic AMP
production, increased the mRNA levels for Mmp-7 in the
vas deferens by about 40%, and this increase was main-
tained with longer periods of incubation (Figure 7B).
Discussion
We investigated the distribution of the Rxfp1 and Rxfp2
receptors in the reproductive tract of the male rat. These
two receptors interact with members of the superfamily of
insulin-related hormones, relaxin and Insl3. In human
males, relaxin is produced mainly in the prostate [37,38]
and released primarily if not exclusively into the seminal
fluid [1], where its concentration ranges 1 to 73 ng/mL
[39,40]. On the other hand, in males INSL3 is a major
secretory product of the testicular Leydig cels [41,42] and
is now recognized as a major circulating hormone. In sev-
eral species, relaxin can activate both Rxfp1 and Rxfp2,
and it is still unknown whether the concomitant presence
of both receptors may contribute to the final response to
relaxin.
Our data show that mRNA for Rxfp1 is present in all tested
tissues. High levels were found in the testis and vas defer-
ens, and lower levels in the prostate, Sertoli cells, caput
and cauda epididymis, seminal vesicle, and spermatozoa.
Immunohistochemistry of the testis showed that Rxfp1
protein is especially abundant in late stage germ cells
(elongate spermatids). The location of these receptors on
late stage germ cells and on Sertoli cells suggests a role in
spermatogenesis. However, while disruption of the
relaxin gene is known to cause an arrest in sperm matura-
tion [10], disruption of the Rxfp1 gene does not have the
same effect [18,19].
Immunohistochemistry of the vas deferens showed recep-
tors in longitudinal and circular muscle layers, in the epi-
thelial layer, and in arterioles. It has previously been
shown by immunohistochemistry that relaxin is present
in the vas deferens [43]. This relatively neglected part of
the male reproductive tract has a complex epithelium with
absorptive and secretory functions [44]. Our results sug-
gest that muscular Rxfp1 receptors may be important in
the organization of the extracellular matrix, but they do
not seem to be involved in acute modulation of contrac-
tility. Whether Rxfp1 receptors on the epithelium are
involved in regulation of secretion is not yet clear. The
presence of Rxfp1 in arterioles suggests that relaxin may
regulate local vascular resistance. Both relaxin and Rxfp1
were previously detected in the thoracic aorta and in small
renal and mesenteric arteries [45,46], suggesting a more
general role of the relaxin-Rxfp1 receptor system in the
regulation of local arterial function.
[A] Relaxin fails to affect cyclic AMP production in the vas defer nsFigure 7
[A] Relaxin fails to affect cyclic AMP production in the vas 
deferens. Slices of the vas deferens were incubated for 10 
min with PBS (control), RLX (5 µg/ml) or FKL (50 µM) and 
the cyclic AMP production was measured. Results are mean 
± SEM of 3 independent experiments. * P < 0.05 compared 
to control (Student's t test). [B] Northern blot analysis of the 
effect of relaxin on Mmp-7 mRNA levels in the vas deferens. 
Upper panel shows a representative autoradiogram with 
Mmp-7 and Gapdh mRNA after various periods of incubation 
with relaxin (1 µg/mL). Bottom panel shows densitometric 
analysis of two independent experiments. Error bars indicate 
SEM.Page 9 of 12
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zoa, the levels were low, and Rxfp1 protein was undetect-
able. Nevertheless, the presence of Rxfp1 receptor on
spermatozoa would help explain many studies that sug-
gest that relaxin stimulates sperm motility. For example,
antiserum against relaxin reduces sperm motility [47],
relaxin stimulates sperm motility and attenuates the
decline in the percentage of motile spermatozoa [48],
helps restore decreased sperm motility [48], and improves
penetration of spermatozoa into cervical mucus [50].
Finally, Carrell et al. [50] demonstrated that recombinant
relaxin binds to sperm with high affinity. In contrast, Jock-
enhovel et al. [52] and Newinger et al. [53] failed to find
an effect of relaxin on sperm function. In conclusion, it is
not yet clear if spermatozoa contain functional relaxin
binding sites, and if they do, whether they are alternative
binding sites.
The distribution of Rxfp2 in the testis and epididymis was
recently analyzed by Anand-Ivell et al. [9]. Their finding of
high Rxfp2 levels in late stage germ cells, the presence of
RXFP2 in the epididymis, and the absence of Rxfp2 in Ser-
toli cells is firmly supported by our results. In addition, we
found high levels of Rxfp2 in the vas deferens. Rxfp2 tran-
scripts were also present in the seminal vesicle. The
absence of Rxfp2 transcripts in the prostate of the rat con-
trasts with a study by Klonisch et al. [54] that reported
RXFP2 transcripts in epithelial cells of the human pros-
tate.
Our results also show that the distribution of Rxfp1 and
Rxfp2 is similar in many tissues and both receptors are
expressed in late-stage germ cells. Whether their function
is similar remains to be seen. Disruption of the Rxfp2 gene
causes cryptorchidism, which affects spermatogenesis
[20]. However, it seems that Rxfp2 is not essential for
spermatogenesis, because if the cryptorchidism that
results from the lack of Rxfp2 is surgically corrected at
birth, sperm maturation appears normal [20].
Although Rxfp1 receptors were found in the muscular
layer of the vas deferens, and although relaxin is known to
reduce uterine tone [55], our results clearly suggest that
relaxin is not involved in modulation of contractility in
the vas deferens. Relaxin did not affect spontaneous con-
tractions of the rat vas deferens, did not relax the depolar-
ized contracted organ, and did not affect the contractile
response to noradrenaline, but all these responses were
blocked in control experiments with drugs that affect
cyclic AMP levels such as forskolin or IBMX.
Relaxin can increase cyclic AMP after interacting with
recombinant RXFP1 and RXFP2 in heterologous systems
[2,5,56]. Relaxin can stimulate endogenous receptors to
increase cyclic AMP in many reproductive [55-57,59] and
non-reproductive tissues [3], and other downstream sign-
aling reactions can be activated after production of cyclic
AMP [3]. However, our data clearly indicate that relaxin
does not stimulate the production of cAMP in the vas def-
erens. This result is in accordance with previous observa-
tions [55]. In rat atria and in fibroblasts from the human
lower uterine segment, relaxin also produced little or no
cyclic AMP [60,61]. It remains to be determined whether
other signaling pathways such as the tyrosine kinase sign-
aling pathway mediate relaxin actions in the vas deferens.
It should be pointed out that activation of RXFP2 by
INSL3 reduces cyclic AMP in testicular germ cells and
oocytes, and this effect is prevented by treatment with per-
tussis toxin [62]. Stimulation of the recombinant RXFP2
receptor with INSL3 resulted in a delayed phase coupled
to G0B [56]. Therefore we speculate that the joint presence
of both Rxfp1 and Rxfp2 in the same tissue can result in a
more complex regulation of the cyclic AMP pathway. An
additional complication is the presence of RXFP1 splice
variants, which are found in man [63], rats, and mice [33].
The absence of exon 4 leads to the production of a trun-
cated RXFP1 receptor that can act as an inhibitor of RXFP1
signaling. The Rxfp1 transcripts detected in the present
study in the testis and the vas deferens however did con-
tain exon 4. Splice variants for RXFP2 have also been
reported [64]. In the rat, the Rxfp2 transcripts found so far
in the testis, germ cells and epididymis encoded the full-
length receptor, but the gubernaculum produces a Rxfp2
product that lacks exon 3 [9].
Relaxin is well known for its antifibrotic action and for its
stimulation of the expression and activity of metallopro-
teinases. Metalloproteinases are a family of extracellular
proteases that interfere with the matrix remodeling by
their ability to degrade extracellular matrix components
including collagen. Relaxin increases the expression of
MMP-2, MMP-9 and MMP-3 in uterine and other tissues
[65,65,66,15]. Relaxin has also been shown to enhance
in-vitro invasiveness of breast cancer cells, where it
increases the production of several metalloproteinases,
including MMP-7 [67]. In turn MMP-7 activates MMP-1, -
2 -8 and -9 [36]. The majority of the metalloproteinases
are produced by mesenchymal cells in the stroma,
whereas MMP-7 expression is restricted to epithelium,
particularly glandular epithelium [34,22]. Messenger RNA
for MMP-7 has been found in epithelial cells lining the
efferent duct and in prostatic epithelial cells in mouse and
human, and MMP-7 activity has also been detected in
human semen [23]. This expression pattern of MMP-7
almost exclusively to reproductive tissues suggests a role
in the reproductive function. We here show that MMP-7
mRNA is also present in the vas deferens and is increased
by relaxin, suggesting a role for relaxin with regulation of
extracellular matrix components, including other MMPsPage 10 of 12
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shown in other tissues. A significant increase in the colla-
gen expression in the prostate and testis of relaxin knock-
out mice has been documented before [10].
Conclusion
In this study we detected by RT-PCR and Southern blot the
presence of transcripts for the GPCRs Rxfp1 and Rxfp2,
both of which are present throughout the male reproduc-
tive tract. Rxfp1 on spermatids and Sertoli cells may be
important in spermatogenesis. Relaxin in the vas deferens
is not involved with contractility, but is probably involved
with vascular compliance and collagen and matrix remod-
eling and/or apoptosis.
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